Curetis shall hold its Annual General Shareholders' Meeting on June 16, 2016
(Thomson Reuters ONE) -
Curetis AG /
Curetis shall hold its Annual General Shareholders' Meeting on June 16, 2016
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
- Nominating Dr. Prabhavathi Fernandes for election to its Supervisory Board
Amsterdam, the Netherlands and Holzgerlingen, Germany, May 2, 2016 -- Curetis
N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of
next-level molecular diagnostic solutions, today announced the invitation to its
annual general shareholders' meeting ("AGM").
Curetis will hold its AGM on June 16, 2016, at Steigenberger Hotel,
Stationsplein Zuid-West 951, 1117 CE Schiphol-Oost/Amsterdam, the Netherlands.
The meeting is scheduled to commence at 13.30 hours CEST; registration starts at
12.30 hours CEST. Also Curetis will be offering electronic pre-voting starting
on May 20, 2016 at 08:00 hours CEST.
A copy of the convening notice for the AGM, including a description of the
formalities to participate in the AGM, is available at
http://www.curetis.com/en/investors/share-information/annual-general-
meeting.html
The most important resolutions in the agenda of the AGM relate to changes in the
Supervisory Board, i.e. the proposed election of new Supervisory Board member
Dr. Prabhavathi Fernandes (CEO of Cempra Pharmaceuticals, Inc., Chapel Hill, NC,
USA) for a three-year term until 2019, the resignation of Dr. Frank Mühlenbeck
and the re-election of Dr. Holger Reithinger and Dr. Rudy Dekeyser for another
one-year term, respectively.
Also on the agenda is the creation of a new Stock Option Program for the Company
and associated changes to the Supervisory Board remuneration, making Supervisory
Board members also eligible to such new plan, as well as changes to the
Management Board's Remuneration Policy and Stock Option grants.
Disclaimer
CAUTION - Investigational device. Limited by Federal (or United States) law to
investigational use. The information contained in this communication does not
constitute nor imply an offer to sell or transfer any product, and no product
based on the Curetis Unyvero technology is currently available for sale in the
United States of America or Canada. The analytical and clinical performance
characteristics of any Curetis Unyvero product which may be sold at some future
point in time in the U.S. have not yet been established.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million. The company
is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed
collaboration agreements with Heraeus Medical and Cempra Inc. as well as several
international distribution agreements covering many countries across Europe, the
Middle East and Asia.
For further information, please visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
According to §§ 190 ff. German Reorganization Act (UmwG) and by way of enrolment
in the commercial register at district court Stuttgart on March 15, 2016 Curetis
plc (AG) changed its legal form into Curetis Ltd. (GmbH).
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info((at))akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
Curetis_Logo:
http://hugin.info/171382/R/2008325/742804.jpg
20160502_PR_Curetis_EN:
http://hugin.info/171382/R/2008325/742803.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Curetis AG via GlobeNewswire
[HUG#2008325]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Santacruz Silver Reports Fourth Quarter / Year-End 2015 Financial ResultsDatum: 02.05.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 467769
Anzahl Zeichen: 7034
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 339 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Curetis shall hold its Annual General Shareholders' Meeting on June 16, 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
